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Abstract
Background: Type 2 diabetes is a well-established risk factor for cardiovascular disease and is common among
patients with acute myocardial infarction (MI). The extent to which patients with first-time MI develop diabetes
requiring glucose-lowering medications (GLM) is largely unknown. The aim of the study was to investigate
temporal trends in the initiation of GLM among patients discharged after first-time MI.
Methods: All Danish residents aged ≥ 30 years without prior diabetes hospitalized with first-time MI between 1997
and 2006 were identified by individual-level-linkage of nationwide registers. Initiation of GLM during follow-up was
assessed by claimed prescriptions from pharmacies. Temporal trends in initiation of GLM were assessed by
incidence rate calculations in the MI population as in the general population. Multivariable Cox proportional-hazard
models were used to investigate the likelihood of initiating GLM within a year post-MI.
Results: The population comprised 66,788 patients. Among these patients 3962 patients initiated GLM, of whom
1567 started within one year post-MI. An increase in incidence rates of GLM initiation in the MI population from
19.6 per 1000 person years in 1997 to approximately 27.6 in 2001 was demonstrated. After 2001 the incidence
rates stabilized. A similar trend was observed in the general population where the incidence rates increased from
2.8 in 1997 to 4.0 in 2004 and then stabilized.
Conclusion: Our study demonstrated an increase in incidence rates of GLM initiation within the first year post- MI.
A similar trend was observed in the general population suggesting that the increase in GLM among MI patients
was primarily the effect of a general increased awareness of diabetes. From a public heath perspective, this study
underscores a continuous need for diagnostic and therapeutic improvement in the care of MI patients that
develop diabetes.
Background
Type 2 diabetes is a well-established risk factor for car-
diovascular disease and is common among patients with
acute myocardial infarction (MI), where the prevalence
is as high as 20% [1]. Previous studies have shown that
abnormal glucose metabolism is more common than
normal glucose tolerance among patients with MI and
that abnormal glucose tolerance is an important predic-
tor of impaired long-term outcome in these patients
[2-4]. Thus, among patients with MI without known
diabetes up to 65% exhibit abnormal glucose regulation
when challenged with an oral glucose tolerance test
(OGTT) and 25% of these have values diagnostic for
diabetes and 40% have impaired glucose tolerance [5].
Focus on the adverse prognosis carried by diabetes in
post-MI patients has increased over the years, causing
new guidelines to be developed in 2007. These recom-
mend that patients without diabetes admitted with MI
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MI [5,6]. However, information regarding the actual
number of patients receiving glucose-lowering medica-
tions (GLM) after first-time MI on a population basis is
lacking. We therefore conducted the present nationwide
register-based study to investigate the temporal trends
in the initiation of GLM following hospitalization for
first-time MI between 1997 and 2006.
Methods
Population and Data Sources
All residents in Denmark have a unique and permanent
civil registration number that enables individual-level-
linkage between nationwide registers. The study popula-
tion was identified employing the Danish Civil Registration
system. All medications dispensed from pharmacies were
obtained from the National Prescription Register (the
Danish Register of Medicinal Product Statistics), which
holds information on all prescriptions dispensed from
Danish pharmacies since 1995. The prescription register
keeps information on date of dispensing, strength and
quantity. All drugs are coded according to the Anatomi-
cal Therapeutic Chemical (ATC) classification system.
Information on hospital admissions was obtained from
the Danish National Patient Register, which keeps
records on all hospital admissions in Denmark since
1978 [7]. Each hospitalization is registered at discharge
with diagnoses recorded using the International Classifi-
cation of Diseases (ICD), until 1994 the 8
th revision
(ICD-8) and from 1994 the 10
th revision (ICD-10). All
deaths were identified from the Central Population Regis-
ter where deaths are recorded within 2 weeks.
The study population comprised all patients aged 30
years or older at the start of the study period and
admitted to the hospital between January 1, 1997 and
31, December, 2006 with a primary or secondary diag-
nosis of first-time MI (ICD-10 code I21, I22). First-time
admission for MI implied that the National Patient Reg-
ister had not registered any prior admission for MI in
the previous 19 years. To fully ensure that data available
from the National Prescription Register were complete
inclusion of patients were selected from the year 1997.
The diagnosis of MI in the National Patient Register has
proved to be valid with a sensitivity of 91% and a posi-
tive predictive value of 93% [8]. Diabetes was defined
according to prescription claims for GLM. Thus,
patients who had claimed any prescriptions for GLM
prior to MI hospitalization were not included and
patients that developed diabetes requiring GLM were
identified as individuals initiating GLM (oral or insulin;
ATC code A10) after first-time MI during the study per-
iod, i.e. between January 1, 1997 and December 31,
2006. Patients receiving GLM prior to January 1, 1997
were excluded.
The study population was divided into five two-year
periods in order to study the temporal trends in initia-
tion of GLM.
The general population comprised all individuals at
least 30 years of age and alive on January 1, 1997. The
population was updated on a yearly basis allowing
entrance of new subjects at least 30 years of age per Jan-
uary 1, the following year. Patients with a previous MI
as well as patients with incident MI were excluded from
the general population as were patients treated with
GLM prior to January 1, 1997.
Comorbidity
Comorbidity was assessed using the Ontario Myocardial
Infarction Mortality Prediction Rules for ICD-10 codes
based on diagnoses from the index hospitalization with
MI and up to one year prior to discharge from index
hospitalization (diabetes diagnoses excluded) [9].
Glucose-lowering medication
For determination of first initiated GLM, the following
agents (ATC-codes) were identified: insulin (A10A),
metformin (A10BA02), sulfonylureas (A10BB), glitazones
(A10BG,; acarbose (A10F01), repaglinide (A10BX0) and
metformin+repaglinide (A10BD03). Since only 47 patients
were treated with glitazones, acarbose, repaglinide and
metformin + repaglinide as their first GLM, we com-
bined these treatment groups in one group denoted
‘other GLM’.
Statistical analyses
Continuous variables are presented as mean with stan-
dard deviation (SD). Categorical data are presented as
percentages. The demographic characteristics are pre-
sented for the five study periods outlined above.
Incidence rates (per 1000 person-years) in initiation of
GLM within a year post-MI were calculated leaving out
year 2006 due to incomplete follow-up time. To investi-
gate whether the temporal trends in treatment were an
effect of increased focus of diabetes in MI patients, or
whether similar trends were seen in the general popula-
tion, incidence rates in initiation of GLM was also cal-
culated in the general population.
Multivariable Cox proportional-hazard models
(adjusted by age, gender calendar year) were used to
investigate the likelihood of initiating GLM within a
year post-MI according to the different treatment
years. In this analysis the study period was divided into
five two-year periods using year 1997-98 as the refer-
ence group.
Temporal trends in initiation of different pharmaco-
logical types of first initiated GLM was done in
percentages also with the study period divided into
five two year periods. Test for temporal trends in
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were done by Cochran-Armitage trend test.
All statistical calculations were performed with SAS
statistical software package, version 9.1 (SAS Institute
Inc, Cary, NC) and STATA version 11.0 (StataCorp,
College Station, Texas).
Ethics
The Danish Data Protection Agency approved the study
(No. 2007-41-1667). Retrospective register based studies
in which individuals cannot be identified do not need
ethical approval in Denmark.
Results
Population
In total 89,448 patients ≥ 30 years of age were diagnosed
with first-time MI during the study period. Of these,
77,147 had never used GLM prior to study start. In
total 66,788 were alive at discharge and therefore
formed the present study population.
A total of 3962 patients initiated GLM treatment dur-
ing the study period. Within the first year post discharge
from first-time MI 1567 patients initiated GLM. A total
of 1452 patients were included in the incidence rate
analysis since the 115 patients initiating GLM in 2006
were excluded, due to incomplete follow-up time. As
shown in Table 1, the study population comprised an
excess of males and the mean age was 68-69 years in all
five study cohorts. Information on comorbidity is also
listed in Table 1.
Temporal trends in the incidence of GLM initiation
In the year 1997 the incidence rate of GLM initiation
within the first year after discharge for first-time MI was
approximately 19.6 per 1000 person years. This inci-
dence rate increased until year 2001 (incidence rate
27.6). From 2001 and onwards the incidence rate stabi-
lized, Figure 1.
The probability of initiation of GLM within the study
period increased to a maximum in 2003-2004, HR cor-
responding to 1.42 (95% CI 1.20-1.67; p-value < 0.0001),
when using year of 1997-1998 as a reference, Table 2.
This corresponds to the highest incidence rate of GLM
initiation in 2003 of 28.4 per 1000 person years.
A similar trend in increased incidence rates was
observed in the general population. The incidence rate
increased from 2.8 to 4.0 per 1000 person years in
2004. Following year 2004 the incidence rate stabilized,
Figure 2.
Temporal trends in type of first initiated GLM
In the entire population initiating GLM after first-time
MI, the two predominantly prescribed GLMs were sulfo-
nylureas and metformin, Table 3. During the study per-
iod the use of metformin as first GLM increased
significantly from 30.5% in 1997-1998 to 40.0% in 2005-
2006 (p for trend < 0.0001). Conversely, the use of sul-
fonylureas decreased from 59.0% in 1997-1998 to 45.5%
in 2005-2006 (p for trend < 0.0001). The use of insulin
as first-GLM also increased from 9.1% in 1997-1998 to
14.3% in 2005-2006 (p for trend < 0.002).
Discussion
Our study demonstrated an increase in the incidence rate
of GLM initiation within the first year after first-time MI
from 19.6 per 1000 person years in 1997 to 27.6 per 1000
person-years in 2001. Following year 2001 the incidence
rates stabilized. The increased probability of initiating
Table 1 Demographic characteristics at the time of first-time myocardial infarction according to year of occurrence
1997-1998 1999-2000 2001-2002 2003-2004 2005-2006
Patients with first-time MI
a 11 968 12 383 14 734 14 650 13 053
Patients initiating GLM
b within a year post-MI 227 266 389 389 296
Men (%) 64.0 62.4 61.6 62.1 62.4
Mean age (SD) 67.8 (12.9) 68.5 (13.1) 69.3 (13.1) 69.4 (13.2) 69.4 (13.2)
Comorbidity
c
Congestive heart failure (%) 9.3 12.1 12.9 11.4 10.3
Cardiac arrhythmias (%) 7.3 9.4 10.9 11.5 11.1
PVD
d (%) 1.9 2.3 2.5 2.3 2.3
CVD
e (%) 3.4 4.5 4.9 5.1 4.8
Renal disease (%) 0.8 1.7 2.1 2.3 2.3
Cancer (%) 2.0 2.4 2.9 2.9 2.9
Shock (%) 0.6 0.7 1.2 1.3 1.3
COLD
f (%) 4.4 6.0 7.4 7.0 6.4
Peptic ulcer 1.5 1.5 2.0 1.6 1.6
aMI: myocardial infarction;
b GLM: glucose-lowering medication;
ccomorbidity up till one year prior to discharge from index hospitalization;
dPVD: peripheral
vascular disease;
e CVD: cerebrovascular disease;
f COLD: chronic obstructive lung disease.
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analyses. A similar trend in the increased incident rate in
GLM initiation was demonstrated in the general popula-
tion from 2.8 per 1000 person years in 1997 to 4.0 per
1000 person years in 2004. Corresponding to the MI
population a stabilisation in incidence rate was observed
in the general population after 2004. The international
diagnostic criteria for diabetes was changed from a fasting
blood glucose value of 7.0 mM to 6.1 mM in 1997, mark-
ing the initiation of this nation-wide observational study,
why we cannot exclude the possibility that an unknown
proportion of the increased incidence of diabetes during
t h ep e r i o df r o m1 9 9 7u n t i l2 0 0 1w a si nf a c td u et ot h e
subsequent implementation in clinical practice of these
novel diagnostic criteria in Denmark. However, it should
be noted that the criteria on diabetes/pre-diabetes was not
changed in Denmark during the study period, [10], oppo-
site to what happened in the US in 2003, where the cut-off
point of impaired fasting glucose was further lowered to
5.6 mmol/L by the American Diabetes Association (ADA)
[11]. Nevertheless, the theoretical possibility that the
increased general use of GLM during the period from
1997 until 2001 to some (unknown) extent may be due to
the implementation more stringent diagnostic criteria for
diabetes, in fact support and substantiate the main conclu-
sion of the current work being that diabetes remain dis-
proportionately under diagnosed and under treated among
the high risk proportion of patients developing diabetes
after a MI.
Previously, studies in MI patients have documented
that abnormal glucose metabolism before discharge is
Figure 1 Incidence rate per 1000 person years in initiation of glucose lowering medication (GLM) within a year following for first-time
myocardial infarction.
Table 2 Adjusted Cox proportional hazard model:
Probability of initiating Glucose-lowering medications
within a year post-myocardial infarction adjusted by age,
gender calendar year and stratified by year group
Variable Hazard Ratio 95% CI P
1997-1998 1.00
1999-2000 1.13 0.95-1.35 0.17
2001-2002 1.40 1.19-1.65 <0.0001
2003-2004 1.42 1.20-1.67 <0.0001
2005-2006 1.37 1.15-1.63 0.0004
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Indeed, the Euro Heart Survey on Diabetes and the Heart
with data from 25 countries disclosed unrecognized dia-
betes in 22% of patients with acute coronary syndrome
according to results of the OGTT [3,13]. In addition,
Norhammar et al. conducted a small-scale prospective
study of 181 consecutively admitted MI patients without
known diabetes, where an OGTT was performed at dis-
charge and again 3 months later. According to the
OGTT, 35% and 40% had impaired glucose tolerance at
discharge and after 3 months, respectively and 31% and
25% had previously undiagnosed diabetes [11]. Similar
results were also found by Egstrup et al [2,14].
These results indicate that a large proportion of post-
MI patients have undiagnosed diabetes or develop dia-
betes during admission or within a short time-span after
discharge. We therefore anticipated that a much larger
proportion of patients would have initiated GLM shortly
after discharge for MI, than observed in our current
study. There are numerous possible explanations for
this discrepancy. First, diabetes in many patients was
probably left undiagnosed, because the majority of
patients presented with normal fasting glucose values
and therefore in accord with contemporary guidelines,
did not undergo an OGTT, although many would here
have impaired glucose tolerance or overt diabetes [2].
Figure 2 Incidence rate per 1000 person years in initiation of glucose lowering medication (GLM) in the general population.
Table 3 Distribution of first prescription claimed for glucose-lowering medications according to year of first-time
myocardial infarction
1997-1998 1999-2000 2001-2002 2003-2004 2005-2006 p for trend.
Metformin (%) 30.47 33.83 36.62 38.03 39.94 <0.0001
Insulin (%) 9.07 9.59 12.70 13.25 14.29 0.002
Sulfonylurea (%) 59.07 55.43 48.90 48.01 45.48 <0.0001
Other GLM(%)
a 1.38 1.16 1.78 0.71 0.29 0.15
aGLM: glucose-lowering medications: Other GLM: glitazones, acarbose, repaglinide, and repaglinide + metformin.
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prior to publication of prevailing international guide-
lines, these numbers should not be interpreted as repre-
senting a predominant negligence from clinicians.
Second, guidelines regarding management of newly
detected diabetes at the time of the study generally
recommended lifestyle intervention and dietary treat-
ment as first-line treatment. Therefore it is conceivable
that a substantial number of patients not initiating GLM
were in fact being managed by non pharmacological
intervention. However, since diabetes is well-established
as an important independent long-term prognostic fac-
tor after MI that predicts increased mortality even
17 years after MI, [15] our study underscores the impor-
tance of an aggressive diagnostic and therapeutic
approach in diabetes patients with MI. It is highly unli-
kely that lifestyle interventions were sufficient for all
diabetes patients not initiating GLM to have reached
target blood glucose values, and our results indicate that
a considerable number of post-MI patients do not
receive GLM as appropriate. This is, however, only an
assumption as we e.g. do not have any measurements of
blood glucose values during and after hospitalization.
In agreement with the results cited above, treatment
guidelines have recommended that all patients hospita-
lized with MI have a fasting glucose measurement dur-
ing hospitalization, and are subjected to an OGTT three
months after discharge [5,6]. Furthermore, management
of patients with diabetes with lifestyle interventions
(including dietary treatment) alone is no longer consid-
ered to be first- line treatment. In addition to such
interventions, patients with newly diagnosed diabetes
should initiate treatment with metformin unless contra-
indicated [16]. Therefore, it would be of great interest to
repeat the current study in the future, investigating the
impact of the change of treatment guidelines in this real
life population-scale setting.
During the 10 year study period a considerable
increase in initiation of GLM in the general population
was apparent. The incidence of diabetes in our study
was in consistency with a previous study employing the
Danish National Diabetes Register, where Carstensen et
al. demonstrated an increase in the incidence of diabetes
[17]. Whether the increase in incidence of diabetes in
Denmark represents a true epidemiologic increment in
diabetes rates is questionable, and other possible expla-
nations include 1) increased diagnostic intensity due to
an augmentation of the awareness of diabetes in the
general population, and 2) a large undiagnosed popula-
tion of patients with diabetes early in the study period
was being diagnosed during the rest of the study period,
and 3) a decrease in mortality rates in the general popu-
lation leading to increased numbers of subjects at risk
of diabetes. The extent to which these individual factors
each contribute to the increase in incidence of diabetes
is speculative. A very important discrepancy in our
study compared with the study by Carstensen et al. was
that we only documented an increase in incidence of
patients with diabetes requiring GLM. Supplementary to
the explanations outlined above, we speculate that an
increased awareness during the 10 year study period of
the importance of reaching normoglycaemia in diabetes
patients with use of GLM may also contribute to our
finding of increased incident diabetes.
We would have anticipated a steeper increase in inci-
dence rate in the post-MI population compared to the
general population. Indeed the incidence rates are much
higher in the MI population than in the general popula-
tion, which is not surprising, since MI patients are at
much higher risk of developing diabetes and since dia-
b e t e si sar i s kf a c t o rf o rM I .I ft h eh i g h e ri n c i d e n c e
rates in the MI population compared to the general
population were solely to be explained by a true
increased awareness of diabetes in the MI population
and not in the general population as a whole, a steeper,
linear or even exponential increment of incident dia-
betes in the MI population would be expected. Since we
did not find such steep increase, it is most likely that
the increased initiation of GLM in the MI population
was, in fact, primarily the effect of a general increased
awareness of diabetes in the population as a whole.
Results from randomized controlled trials have con-
clusively demonstrated that the risk of microvascular
complications can be reduced by intensive glycaemic
control in patients with diabetes [18-22]. Although the
effect of intensive glycaemic control on macrovascular
outcomes remains a matter of intense debate, [23-25]
the American Diabetes Association (ADA) currently sta-
ted that glycaemic control early in the course of type 2
diabetes may provide CVD benefits and that glycaemic
control may play a greater role for CVD prevention in
patients with a shorter duration of diabetes before
macrovascular disease is established [26].
It is known that patients with diabetes and cardiovas-
cular disease tend to have poorer glycaemic control than
those with diabetes without cardiovascular disease, indi-
cating the need for increased attention to glycaemic
control in patients with cardiovascular disease [27]. The
current results shows that when it comes to early GLM
initiation in those with newly detected diabetes, there
remains a considerable room for improvement in mod-
ern clinical practice.
The change in the pattern of type of GLM used in MI
patients during the period is likely to reflect the results
of the UKPDS as well as the Diabetes Mellitus, Insulin
Glucose Infusion in Acute Myocardial Infarction Study
1 signaling increased survival among users of metformin
in general as well as the value of early insulin treatment
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also for patients undergoing percutaneous intervention
(PCI), in whom the use of metformin or thiazolidine-
diones seem to attenuate the re-stenosis formation [13].
Opposite, the effect of sulfonylureas or insulin on out-
comes in MI patients treated with and without PCI
seems to be less beneficial [29,30]. The extent to which
our findings of changes in clinical practice may change
the long-time survival in Danish MI patients with dia-
betes remain to be determined.
Strengths and limitations
This study is based on complete and nationwide data
obtained from registers that previously have been vali-
dated and shown to be reliable. The data cover the entire
population of Denmark independent of socioeconomic
status, age or participation in specific health-insurance
programs. Therefore, the risk of selection bias is reduced,
and the study notably includes citizens both in and out of
the labor market. The Danish health care system partially
reimburses drug expenses, and all Danish pharmacies are
required to register all dispensed drug prescriptions,
ensuring complete registration. There are, however,
important limitations that need to be addressed. We lack
information about additional factors influencing the deci-
sion for initiation of GLM, and other unmeasured con-
founders. Furthermore, we were unable to identify type 1
and type 2 diabetes among the insulin users and we
could not assess the duration of diabetes prior to initia-
tion of GLM in our study, since the registers do not hold
information on HBA1c, fasting blood glucose, and other
clinical characteristics, e.g. body mass index (BMI).
T h ed i a g n o s t i cc r i t e r i af o rM Ic h a n g e di n1 9 9 9a n d
more sensitive diagnostic markers were introduced (i.e.
troponins) during the study period, which potentially may
have influenced our results, although e.g. a previous study
indicated no change in survival for MI patients [31].
Conclusions and clinical implication
Our study demonstrated an increase in incidence rates
of GLM initiation within the first year post- MI. Parallel,
a similar trend was observed in the general population.
These results indicate that the increased initiation of
GLM in the MI population was primarily the effect of a
general increased awareness of diabetes in the popula-
tion as a whole. From a public heath perspective, this
study underscores a continuous need for diagnostic and
therapeutic improvement in the care of MI patients that
develop diabetes, and such strategy is likely to provide
long-term benefits.
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